Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.

Ayumi Kodama, Hideto To, Tomohiro Kinoshita, Ichiro Ieiri, Shun Higuchi

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: The combination of cisplatin and docetaxel shows a better cure rate against non-small-cell lung cancer than other drug combinations in clinical studies; however, severe myelosuppression and nephrotoxicity are dose-limiting factors. The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects. METHODS: Cisplatin and docetaxel were administered i.p. to male ICR mice simultaneously, or sequentially with either cisplatin or docetaxel first followed by the second drug 12 h later (docetaxel-cisplatin and cisplatin-docetaxel groups). Antitumour effects of these schedules were also tested in C57BL/6N mice bearing Lewis lung carcinomas. KEY FINDINGS: The simultaneous docetaxel/cisplatin group showed the lowest survival rate and the highest blood urea nitrogen (BUN) concentration. Cisplatin concentrations in the plasma and kidney were higher in the simultaneous dosing group than the sequential dosing groups. Antitumour effect was the greatest in the docetaxel-cisplatin group. CONCLUSIONS: The docetaxel-cisplatin regimen inhibited tumour growth the best and reduced mortality and nephrotoxicity.

Original languageEnglish
Pages (from-to)615-621
Number of pages7
JournalThe Journal of pharmacy and pharmacology
Volume61
Issue number5
DOIs
Publication statusPublished - May 1 2009

Fingerprint

docetaxel
Cisplatin
Appointments and Schedules
Lewis Lung Carcinoma
Inbred ICR Mouse
Blood Urea Nitrogen
Drug Combinations
Inbred C57BL Mouse

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. / Kodama, Ayumi; To, Hideto; Kinoshita, Tomohiro; Ieiri, Ichiro; Higuchi, Shun.

In: The Journal of pharmacy and pharmacology, Vol. 61, No. 5, 01.05.2009, p. 615-621.

Research output: Contribution to journalArticle

@article{0f105013ae4b461c8681f4675dfa66b0,
title = "Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.",
abstract = "OBJECTIVES: The combination of cisplatin and docetaxel shows a better cure rate against non-small-cell lung cancer than other drug combinations in clinical studies; however, severe myelosuppression and nephrotoxicity are dose-limiting factors. The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects. METHODS: Cisplatin and docetaxel were administered i.p. to male ICR mice simultaneously, or sequentially with either cisplatin or docetaxel first followed by the second drug 12 h later (docetaxel-cisplatin and cisplatin-docetaxel groups). Antitumour effects of these schedules were also tested in C57BL/6N mice bearing Lewis lung carcinomas. KEY FINDINGS: The simultaneous docetaxel/cisplatin group showed the lowest survival rate and the highest blood urea nitrogen (BUN) concentration. Cisplatin concentrations in the plasma and kidney were higher in the simultaneous dosing group than the sequential dosing groups. Antitumour effect was the greatest in the docetaxel-cisplatin group. CONCLUSIONS: The docetaxel-cisplatin regimen inhibited tumour growth the best and reduced mortality and nephrotoxicity.",
author = "Ayumi Kodama and Hideto To and Tomohiro Kinoshita and Ichiro Ieiri and Shun Higuchi",
year = "2009",
month = "5",
day = "1",
doi = "10.1211/jpp/61.05.0010",
language = "English",
volume = "61",
pages = "615--621",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "5",

}

TY - JOUR

T1 - Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.

AU - Kodama, Ayumi

AU - To, Hideto

AU - Kinoshita, Tomohiro

AU - Ieiri, Ichiro

AU - Higuchi, Shun

PY - 2009/5/1

Y1 - 2009/5/1

N2 - OBJECTIVES: The combination of cisplatin and docetaxel shows a better cure rate against non-small-cell lung cancer than other drug combinations in clinical studies; however, severe myelosuppression and nephrotoxicity are dose-limiting factors. The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects. METHODS: Cisplatin and docetaxel were administered i.p. to male ICR mice simultaneously, or sequentially with either cisplatin or docetaxel first followed by the second drug 12 h later (docetaxel-cisplatin and cisplatin-docetaxel groups). Antitumour effects of these schedules were also tested in C57BL/6N mice bearing Lewis lung carcinomas. KEY FINDINGS: The simultaneous docetaxel/cisplatin group showed the lowest survival rate and the highest blood urea nitrogen (BUN) concentration. Cisplatin concentrations in the plasma and kidney were higher in the simultaneous dosing group than the sequential dosing groups. Antitumour effect was the greatest in the docetaxel-cisplatin group. CONCLUSIONS: The docetaxel-cisplatin regimen inhibited tumour growth the best and reduced mortality and nephrotoxicity.

AB - OBJECTIVES: The combination of cisplatin and docetaxel shows a better cure rate against non-small-cell lung cancer than other drug combinations in clinical studies; however, severe myelosuppression and nephrotoxicity are dose-limiting factors. The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects. METHODS: Cisplatin and docetaxel were administered i.p. to male ICR mice simultaneously, or sequentially with either cisplatin or docetaxel first followed by the second drug 12 h later (docetaxel-cisplatin and cisplatin-docetaxel groups). Antitumour effects of these schedules were also tested in C57BL/6N mice bearing Lewis lung carcinomas. KEY FINDINGS: The simultaneous docetaxel/cisplatin group showed the lowest survival rate and the highest blood urea nitrogen (BUN) concentration. Cisplatin concentrations in the plasma and kidney were higher in the simultaneous dosing group than the sequential dosing groups. Antitumour effect was the greatest in the docetaxel-cisplatin group. CONCLUSIONS: The docetaxel-cisplatin regimen inhibited tumour growth the best and reduced mortality and nephrotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=68949129102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949129102&partnerID=8YFLogxK

U2 - 10.1211/jpp/61.05.0010

DO - 10.1211/jpp/61.05.0010

M3 - Article

C2 - 19406000

VL - 61

SP - 615

EP - 621

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 5

ER -